The final mechanism by which the tested drugs alleviate IAA-induced ulcerative colitis was by their anti-fibrotic effect manifested by the reduction of the TGF-β1/α-SMA axis and the enhancement of SMAD-7, effects that were reverted by the ulcerogenic inducer. Here, ACTA1 is linked to ulcerative colitis.